Literature DB >> 6809473

The individual variation in pharmacokinetics and pharmacodynamics of furosemide in young normal male subjects.

F Andreasen, C K Christensen, F K Jacobsen, J Jansen, C E Mogensen, O L Pedersen.   

Abstract

Following a 24 h control period in the ward 80 mg furosemide was injected intravenously to ten young healthy, male volunteers. The serum clearance of furosemide (Cls) was between 140 and 201 ml min-1 and on the average the renal clearance was 60% of Cls. During the initial 30 min period a maximum additional excretion rate of sodium of 3.3 mmol min-1 was reached at an excretion rate of 0.8 mg furosemide min-1. A marked initial drop in creatinine clearance (Clcr) was noted and Clcr(24 h) showed an average decrease of 12% after the drug administration. The serum concentration of potassium was decreased at 1 and 2 h after the injection and of sodium from 2 h and on. The concentration of albumin in serum increased by 3% (P less than 0.05) already after 5 min. After 2 h a maximum increase of 14% was reached. After 8 min diastolic blood pressure was increased by 13% (P less than 0.05), whereas systolic blood pressure reached a significant decrease gradually (7% after 3 h).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6809473     DOI: 10.1111/j.1365-2362.1982.tb01000.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  13 in total

Review 1.  Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II).

Authors:  L L Ponto; R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

2.  The pharmacokinetics of frusemide are influenced by age.

Authors:  F Andreasen; U Hansen; S E Husted; J A Jansen
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

3.  The influence of age on renal and extrarenal effects of frusemide.

Authors:  F Andreasen; U Hansen; S E Husted; C E Mogensen; E B Pedersen
Journal:  Br J Clin Pharmacol       Date:  1984-07       Impact factor: 4.335

4.  Furosemide disposition in patients on CAPD.

Authors:  U Martin; R J Winney; L F Prescott
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

5.  Urinary excretion and diuretic action of furosemide in rats: increased response to the urinary excretion rate of furosemide in rats with acute renal failure.

Authors:  T Kikkoji; A Kamiya; K Inui; R Hori
Journal:  Pharm Res       Date:  1988-11       Impact factor: 4.200

6.  A quantitative method of evaluating the diuretic response to furosemide in rats.

Authors:  R Hori; K Okumura; K Inui; T Shibata; T Kikkoji; A Kamiya
Journal:  Pharm Res       Date:  1988-11       Impact factor: 4.200

7.  Furosemide, fenclofenac, diclofenac, mefenamic acid and meclofenamic acid inhibit specific T3 binding in isolated rat hepatic nuclei.

Authors:  D J Topliss; P S Hamblin; E Kolliniatis; C F Lim; J R Stockigt
Journal:  J Endocrinol Invest       Date:  1988-05       Impact factor: 4.256

8.  Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis.

Authors:  M M Hammarlund; L K Paalzow; B Odlind
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

9.  Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous furosemide.

Authors:  T Li; M G Lee; W L Chiou
Journal:  J Pharmacokinet Biopharm       Date:  1986-10

Review 10.  Pharmacokinetic changes in patients with oedema.

Authors:  B Vrhovac; N Sarapa; I Bakran; M Huic; V Macolic-Sarinic; I Francetic; A Wolf-Coporda; F Plavsic
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.